Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1998 Jul;358(1):127-33.
doi: 10.1007/pl00005233.

Nitric oxide synthases: catalytic function and progress towards selective inhibition

Affiliations
Review

Nitric oxide synthases: catalytic function and progress towards selective inhibition

B Mayer et al. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul.

Abstract

Biosynthesis of nitric oxide (NO) is performed by the dimeric, heme-containing enzyme nitric oxide synthase, which requires the flavins FAD and FMN, as well as the pteridine cofactor (6R)-5,6,7,8-tetrahydro-L-biopterin (H4biopterin) in order to catalyze the NADPH-dependent oxidation of L-arginine. The three major isoforms of nitric oxide synthase (NOS), although identical in that they contain a carboxy-terminal reductase and an amino-terminal oxygenase domain, fulfill diverse physiological functions, according to their differing expression patterns and mechanisms of activation. The pteridine H4biopterin, which affects both the conformational stability and activity of NOS, demonstrates anticooperative binding which results in the stoichiometric production of NO and O2-. Physiological mechanisms involving superoxide dismutase and reduced glutathione exist to avoid the subsequent formation of the potent oxidant peroxynitrite. With regard to inhibition of NO production, novel isoform-selective inhibitors are proving useful not only for dissecting the physiological functions of NOS, but also in the development of novel therapeutic agents.

PubMed Disclaimer

Comment in

  • Pharmacology of NO:cGMP signal transduction.
    Lohse MJ, Förstermann U, Schmidt HH. Lohse MJ, et al. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jul;358(1):111-2. doi: 10.1007/pl00005230. Naunyn Schmiedebergs Arch Pharmacol. 1998. PMID: 9721011 Clinical Trial. No abstract available.

Publication types

LinkOut - more resources